Analyst consensus rating
Ionis Pharmaceuticals Analyst Rating: Buy
Direct answer
Ionis Pharmaceuticals's consensus rating is Buy.
23 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $84.13.
Forecast evidence checked November 1, 2026.
Get free Ionis Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $43.52
- Average price target
- $84.13
- High price target
- $105.00
- Low price target
- $58.00
- Low target gap
- +33.3%
- Target upside
- +93.3%
- High target gap
- +141.3%
- Target range width
- 108%
- Consensus rating
- Buy
- Analysts
- 23
- Evidence date
- November 1, 2026
- Valid through
- November 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $84.13.
How far are Ionis Pharmaceuticals's low and high targets from the recorded price?
The low target implies +33.3%, while the high target implies +141.3%.
How many analysts are included in Ionis Pharmaceuticals's consensus?
The verified consensus includes 23 analysts.
How is Ionis Pharmaceuticals's target upside or downside calculated?
The average target of $84.13 is divided by the recorded price of $43.52, then one is subtracted to produce +93.3%. This does not guarantee a future return.
When was Ionis Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-01. The dataset is valid through 2026-11-08.